Annexin Pharmaceuticals AB Logo

Annexin Pharmaceuticals AB

Clinical-stage biotech developing a cell-protecting biologic for RVO and oncology.

ANNX | ST

Overview

Corporate Details

ISIN(s):
SE0009664154
LEI:
5493000JP703HGPJEX27
Country:
Sweden
Address:
KAMMAKARGATAN 48, 111 60 Stockholm

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on developing ANXV, a recombinant human protein, Annexin A5. This first-in-class biologic acts as a cell protector and immune modulator by targeting and binding to phosphatidylserine (PS), a lipid exposed on the surface of stressed, damaged, or cancerous cells. This mechanism forms a protective shield, counteracting cellular stress, reducing inflammation, and helping damaged cells recover. The company's lead program is evaluating ANXV in a Phase 2 clinical study for the treatment of Retinal Vein Occlusion (RVO), a common cause of vision impairment. ANXV is also being investigated for its potential in oncology, where it may enable the immune system to attack cancer cells. The drug candidate's fundamental mode of action provides broad therapeutic potential across various diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Annexin Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BIOVIE INC. Logo
Develops drug therapies for neurological disorders and advanced liver disease.
United States of America
BIVI
BioXcel Therapeutics, Inc. Logo
Biopharmaceutical company using AI to develop drugs for neuroscience and immuno-oncology.
United States of America
BTAI
Black Diamond Therapeutics, Inc. Logo
Develops precision oncology therapies targeting families of oncogenic mutations.
United States of America
BDTX
BL Pharmtech Corp. Logo
Researches, develops, and sells health foods, supplements, and pharmaceuticals.
South Korea
065170
BNC Korea Co, Ltd Logo
Develops hyaluronic acid-based dermal fillers and botulinum toxin injectables.
South Korea
256840
Boditech Med Inc. Logo
Develops, manufactures, and distributes in-vitro diagnostic (IVD) solutions.
South Korea
206640
BOIRON Logo
A family-owned pharmaceutical laboratory and a world leader in homeopathic medicines.
France
BOI
Manufactures specialty ingredients for the food, pharmaceutical, and cosmetic industries.
South Korea
002760
Bolt Biotherapeutics, Inc. Logo
Clinical-stage biotech developing immuno-oncology therapies using the innate immune system.
United States of America
BOLT
Bone Biologics Corp Logo
Develops a protein-based bone graft substitute for spinal fusion procedures.
United States of America
BBLG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.